Immunology
🇺🇸 FDA Page 4FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global immunology drug development, market trends, and regulatory landscapes. Inform your pharma BD and investment strategy.
Showing 37–48 of 50 articles
Veloxis Pharmaceuticals' Pegrizeprument Receives FDA Orphan Drug Designation for Heart Transplant Rejection Prevention
Dupixent Becomes First Biologic Approved for Children Ages 2-11 with Chronic Spontaneous Urticaria
Sanofi's Tzield Approved by FDA for Children as Young as 1 Year to Delay Type 1 Diabetes Progression
FDA Approves Sanofi's Tzield for Children Age 1+ to Delay Type 1 Diabetes Onset
ACRP 2026: Immunology Clinical Research Trends to Watch
FDA Approves Skin-Renew: New Indication for Severe Eczema
FDA Approves BioClone's Clone-Remicade: Cheaper Alternative to Remicade
Zai Lab's ZL-1503 Bispecific Antibody Shows Rapid Itch Relief in Atopic Disease Preclinical Studies
Zai Lab's ZL-1503 Bispecific Antibody Shows Promise for Rapid Itch Relief in Atopic Dermatitis Preclinical Study
argenx VYVGART Shows Promise Across Multiple Myasthenia Gravis Subtypes in New AAN 2026 Clinical Data
Mabwell's LILRB4/CD3 Bispecific Antibody 6MW5311 Receives NMPA IND Approval for Leukemia Treatment
Nkarta Receives FDA Approval for Outpatient NKX019 Dosing in Autoimmune Disease Treatment